{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:23:23Z","timestamp":1790717003614,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clml.2022.12.009","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:06:51Z","timestamp":1671275211000},"page":"e139-e149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and Safety of Blinatumomab for the Treatment of Relapsed\/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"Heng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.009_bib0001","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.009_bib0002","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.12.009_bib0003","unstructured":"Howlader N, Noone A, Krapcho M, et\u00a0al. SEER cancer statistics review, 1975\u20132018. 2021."},{"key":"10.1016\/j.clml.2022.12.009_bib0004","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4065\/80.11.1517","article-title":"Adult acute lymphoblastic leukemia","volume":"80","author":"Jabbour","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2022.12.009_bib0005","first-page":"23","article-title":"Topics in pediatric leukemia\u2013acute lymphoblastic leukemia","volume":"7","author":"Esparza","year":"2005","journal-title":"MedGenMed"},{"key":"10.1016\/j.clml.2022.12.009_bib0006","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.12.009_bib0007","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.009_bib0008","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1038\/srep04227","article-title":"Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis","volume":"4","author":"Ma","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2022.12.009_bib0009","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.009_bib0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2022.12.009_bib0011","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.12.009_bib0012","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.009_bib0013","first-page":"2465","article-title":"Agents for refractory\/relapsed acute lymphocytic leukemia in adults","volume":"18","author":"Qian","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clml.2022.12.009_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.923419","article-title":"Novel treatments for pediatric relapsed or refractory acute B-cell lineage lymphoblastic leukemia: precision medicine era","volume":"10","author":"Mengxuan","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.clml.2022.12.009_bib0015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.clml.2022.12.009_bib0016","first-page":"7","article-title":"Evaluating Blinatumomab for the Treatment of relapsed\/refractory ALL: design, development, and place in therapy","volume":"10","author":"Sigmund","year":"2020","journal-title":"Blood Lymphatic Cancer"},{"key":"10.1016\/j.clml.2022.12.009_bib0017","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.009_bib0018","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","article-title":"Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia","volume":"102","author":"G\u00f6kbuget","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.009_bib0019","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2022.12.009_bib0020","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.clml.2022.12.009_bib0021","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.009_bib0022","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","article-title":"Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis","volume":"6","author":"Locatelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.009_bib0023","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.009_bib0024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.12.009_bib0025","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.009_bib0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.12.009_bib0027","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/cas.14322","article-title":"Phase 1b\/2 study of blinatumomab in Japanese adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2022.12.009_bib0028","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.009_bib0029","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/cancers14020426","article-title":"Blinatumomab in children and adolescents with relapsed\/refractory B cell precursor acute lymphoblastic leukemia: a real-life multicenter retrospective study in seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers","volume":"14","author":"Beneduce","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2022.12.009_bib0030","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/10428194.2020.1844198","article-title":"Blinatumomab\u2009+\u2009ponatinib for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"62","author":"Couturier","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.12.009_bib0031","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","article-title":"Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party","volume":"98","author":"Jung","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.12.009_bib0032","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/ejh.13569","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"106","author":"Queudeville","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.12.009_bib0033","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.009_bib0034","doi-asserted-by":"crossref","first-page":"e28922","DOI":"10.1002\/pbc.28922","article-title":"Outcomes for Australian children with relapsed\/refractory acute lymphoblastic leukaemia treated with blinatumomab","volume":"68","author":"Sutton","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2022.12.009_bib0035","doi-asserted-by":"crossref","first-page":"e29562","DOI":"10.1002\/pbc.29562","article-title":"Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: results from the NEUF study","volume":"69","author":"Locatelli","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2022.12.009_bib0036","article-title":"Real-world multicenter experience in tumor debulking prior to blinatumomab administration in adult patients with relapsed\/refractory B-Cell precursor acute lymphoblastic leukemia","volume":"11","author":"Bonifacio","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2022.12.009_bib0037","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00277-019-03854-0","article-title":"Safety and efficacy of blinatumomab: a real world data","volume":"99","author":"Apel","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.12.009_bib0038","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/bloodadvances.2019001381","article-title":"Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.009_bib0039","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1177\/1078155218817816","article-title":"FLAG\/FLAG-IDA regimen for children with relapsed\/refractory acute leukemia in the era of targeted novel therapies","volume":"25","author":"Mustafa","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2022.12.009_bib0040","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/j.clml.2020.12.010","article-title":"Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in relapsed\/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes","volume":"21","author":"Aamir","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.009_bib0041","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","article-title":"The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct","volume":"56","author":"Brandl","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2022.12.009_bib0042","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/j.clml.2020.12.008","article-title":"Efficacy and safety of inotuzumab ozogamicin (CMC-544) for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-hodgkin lymphoma: a systematic review and meta-analysis","volume":"21","author":"Li","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.009_bib0043","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.33469","article-title":"Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"127","author":"Jabbour","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.009_bib0044","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:38Z","timestamp":1761871298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2152265022017724"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Blinatumomab for the Treatment of Relapsed\/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}